BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17606765)

  • 1. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.
    Kawamata N; Chen J; Koeffler HP
    Blood; 2007 Oct; 110(7):2667-73. PubMed ID: 17606765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
    Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE
    Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction of cyclin D1 mRNA stability.
    Zhang J; Ouyang W; Li J; Zhang D; Yu Y; Wang Y; Li X; Huang C
    Toxicol Appl Pharmacol; 2012 Sep; 263(2):218-24. PubMed ID: 22749963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
    Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
    Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
    Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
    Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
    Hagiwara K; Kunishima S; Iida H; Miyata Y; Naoe T; Nagai H
    Apoptosis; 2015 Jul; 20(7):975-85. PubMed ID: 25835755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma.
    Dal Col J; Dolcetti R
    Cell Cycle; 2008 Sep; 7(18):2813-6. PubMed ID: 18769147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
    Moros A; Bustany S; Cahu J; Saborit-Villarroya I; Martínez A; Colomer D; Sola B; Roué G
    Clin Cancer Res; 2014 Jan; 20(2):393-403. PubMed ID: 24178620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.
    Vogt N; Abramov D; Koch K; Masqué-Soler N; Szczepanowski M; Klapper W
    Leuk Lymphoma; 2015 Jul; 56(7):2134-40. PubMed ID: 25315075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
    Alinari L; Prince CJ; Edwards RB; Towns WH; Mani R; Lehman A; Zhang X; Jarjoura D; Pan L; Kinghorn AD; Grever MR; Baiocchi RA; Lucas DM
    Clin Cancer Res; 2012 Sep; 18(17):4600-11. PubMed ID: 22791882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
    Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
    Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin.
    Jin JS; Tsao TY; Sun PC; Yu CP; Tzao C
    Pathol Oncol Res; 2012 Jul; 18(3):713-20. PubMed ID: 22270866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM; Roth DM; Marchal C; Bouchecareilh M
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
    Shi W; Han X; Yao J; Yang J; Shi Y
    Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
    Gillenwater AM; Zhong M; Lotan R
    Mol Cancer Ther; 2007 Nov; 6(11):2967-75. PubMed ID: 18025281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.
    Lokvenc M; Kalinova M; Forsterova K; Klener P; Trneny M; Fronkova E; Kodet R
    Ann Hematol; 2018 Mar; 97(3):467-474. PubMed ID: 29273915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.